Cancer stem cells survive treatment partly because of how they feed themselves. Why many of them depend on glutamine, which drugs block that pathway, and what has and has not worked so far.
A transcription factor first found in childhood leukemia turns out to sit near the top of many cancer pathways. What PBX1 does, why it predicts poor outcomes in several tumors, and how researchers are trying to drug it.
Transcription factors have long been considered impossible to target with drugs. By designing a molecule that wedges into the gap between PBX1 and the DNA it reads, we made platinum-resistant ovarian tumors sensitive to chemotherapy again.
Why conventional treatments fail against a rare subpopulation of tumor cells, what makes cancer stem cells so resilient, and how YAS Lab is working to eliminate them.